NCT01323192 - An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder | Biotech Hunter

Enrollment

284

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions

Attention-Deficit Hyperactivity Disorder

Interventions

DRUG

JNS001

Participants will receive JNS001 (18 mg, 36 mg, 54 mg or 72 mg per day) orally once daily for 8 weeks.

DRUG

Placebo

Participants will receive matching placebo orally once daily for 8 weeks.

Trial Locations (30)

Unknown

Chiba

Chigasaki

Chiyoda City

Fuchū

Fukuoka

Fukushima

Hamamatsu

Higashiosaka

Ichikawa

Iruma

Isehara

Kashihara

Kishiwada

Kobe

Kumamoto

Kurume

Matsuyama

Nagasaki

Nagoya

Nara

Neyagawa

Osaka

Saitama

Sakai

Sapporo

Setagaya City

Shibuya City

Takatsuki

Tokyo

Yokohama